Literature DB >> 10936886

Influence of lipoproteins on microglial degradation of Alzheimer's amyloid beta-protein.

G M Cole1, M D Ard.   

Abstract

Amyloid beta-protein (Abeta), the major component of plaques in Alzheimer's disease, is a small hydrophobic protein that is carried on apolipoprotein E (ApoE)- and ApoJ-containing lipoprotein particles in plasma and cerebrospinal fluid (CSF). Microglia, the scavenger cells of the CNS, take up and degrade Abeta via lipoprotein receptors including scavenger receptors A and B, and possibly via other receptors. Lipoproteins, ApoE, and ApoJ influence the uptake and degradation of Abeta in vitro and in vivo. Differences in ApoE-E4, -E3, and -E2 isoforms with respect to Abeta binding to lipoproteins and delivery to cells, including microglia, may contribute to the increased risk of Alzheimer's disease for people with an APOE4 genotype and to risk reduction with APOE2. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10936886     DOI: 10.1002/1097-0029(20000815)50:4<316::AID-JEMT11>3.0.CO;2-E

Source DB:  PubMed          Journal:  Microsc Res Tech        ISSN: 1059-910X            Impact factor:   2.769


  18 in total

Review 1.  Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins.

Authors:  Tien-Phat V Huynh; Albert A Davis; Jason D Ulrich; David M Holtzman
Journal:  J Lipid Res       Date:  2017-02-27       Impact factor: 5.922

Review 2.  Microglial dysfunction in brain aging and Alzheimer's disease.

Authors:  Kira Irving Mosher; Tony Wyss-Coray
Journal:  Biochem Pharmacol       Date:  2014-01-18       Impact factor: 5.858

Review 3.  Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.

Authors:  David M Holtzman; Joachim Herz; Guojun Bu
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

4.  Human APOE genotype affects intraneuronal Aβ1-42 accumulation in a lentiviral gene transfer model.

Authors:  Wenjuan Zhao; Sonya B Dumanis; Irfan Y Tamboli; Gustavo A Rodriguez; Mary Jo Ladu; Charbel E H Moussa; G William Rebeck
Journal:  Hum Mol Genet       Date:  2013-10-23       Impact factor: 6.150

5.  Apolipoproteins in the brain: implications for neurological and psychiatric disorders.

Authors:  David A Elliott; Cyndi Shannon Weickert; Brett Garner
Journal:  Clin Lipidol       Date:  2010-08-01

6.  ApoE mimetic peptide decreases Abeta production in vitro and in vivo.

Authors:  S Sakura Minami; Antoinette Cordova; John R Cirrito; Joseph A Tesoriero; Lenard W Babus; Gary C Davis; Sivanesan Dakshanamurthy; R Scott Turner; Daniel Ts Pak; G William Rebeck; Mikell Paige; Hyang-Sook Hoe
Journal:  Mol Neurodegener       Date:  2010-04-20       Impact factor: 14.195

Review 7.  Current status on Alzheimer disease molecular genetics: from past, to present, to future.

Authors:  Karolien Bettens; Kristel Sleegers; Christine Van Broeckhoven
Journal:  Hum Mol Genet       Date:  2010-04-13       Impact factor: 6.150

8.  Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial.

Authors:  Angela J Hanson; Jennifer L Bayer-Carter; Pattie S Green; Thomas J Montine; Charles W Wilkinson; Laura D Baker; G Stennis Watson; Laura M Bonner; Maureen Callaghan; James B Leverenz; Elaine Tsai; Nadia Postupna; Jing Zhang; Johanna Lampe; Suzanne Craft
Journal:  JAMA Neurol       Date:  2013-08       Impact factor: 18.302

9.  apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain.

Authors:  Rashid Deane; Abhay Sagare; Katie Hamm; Margaret Parisi; Steven Lane; Mary Beth Finn; David M Holtzman; Berislav V Zlokovic
Journal:  J Clin Invest       Date:  2008-11-13       Impact factor: 14.808

Review 10.  ApoE and Abeta1-42 interactions: effects of isoform and conformation on structure and function.

Authors:  Arlene M Manelli; W Blaine Stine; Linda J Van Eldik; Mary Jo LaDu
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.